Evidence map›Paper›PMID 32454097›Full record

ReviewJournal of the American Academy of Dermatology2020

Immune checkpoint inhibitor-related dermatologic adverse events.

Amaris N Geisler, Gregory S Phillips, Dulce M Barrios, Jennifer Wu, Donald Y M Leung, Andrea P Moy, Jeffrey A Kern, Mario E Lacouture

Registry-linked trialOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of the American Academy of Dermatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04283539 (Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer Immunotherapy), which is not on this map. Cited by 269 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
269citing papers in PubMed, 9 pooled it
18.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04283539 completednot on this map

Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer Immunotherapy

TypeobservationalSponsorNational Jewish HealthRan2020 to 2026Enrolled255ConditionsCancer, Skin Disease, Immunotherapy, Patients With Solid Tumors Receiving Immunotherapy With an ICI Will be Randomized to Participate in an SDoH and Side Effects Navigation Program vs. ControlArmssystemic corticosteroid or biologic
3 · Its place in the literature

Who cites it

269 citing papers in PubMed, 9 syntheses or guidelines pooled it, 444 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Exposome Risk Factors for Vitiligo: A Systematic Evidence Review.American journal of clinical dermatology · 2026
    Pooled it
  4. Pooled it
  5. Guideline
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Benralizumab for Eosinophil-Related Cutaneous Adverse Events of Anticancer Therapy: A Phase II Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Trial
  11. Trial
  12. Trial
  13. Article
  14. Article
  15. The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact.Journal of immunotherapy and precision oncology · 2026
    Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Cancer pain.Nature reviews. Disease primers · 2026
    Review

209 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 2 countries.

Amaris N GeislerDermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Gregory S PhillipsState University of New York Downstate Health Sciences University, Brooklyn, New York.
Dulce M BarriosDermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Jennifer WuChang Gung Memorial Hospital Linkou, Chang Gung University School of Medicine, Taoyuan, Taiwan.
Donald Y M LeungDivision of Pediatric Allergy and Immunology, Department of Pediatrics, National Jewish Health, Denver, Colorado.
Andrea P MoyDepartment of Pathology, Memorial Sloan Kettering Cancer, New York, New York.
Jeffrey A KernDivision of Pediatric Allergy and Immunology, Department of Pediatrics, National Jewish Health, Denver, Colorado.
Mario E LacoutureDermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Weill Cornell Medicine, New York, New York. Electronic address: lacoutum@mskcc.org.
Memorial Sloan Kettering Cancer Center · USChang Gung University · TWNational Jewish Health · USSUNY Downstate Health Sciences University · USUniversity of Colorado Denver · USWeill Cornell Medicine · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
SEAL (Stopping Atopic dermatitis and ALlergy) Study: Prevent allergy by enhancing the skin barrierU01AI147462 · NIAID · STANFORD UNIVERSITY · PI Mary Johnson, GIDEON LACK · 2020 to 2026
$14.0M
Identification of pathways to mitigate Immune-Related Adverse Events with Cancer Immunotherapy U01AR077511 · NIAMS · NATIONAL JEWISH HEALTH · PI KERN, JEFFREY A, LACOUTURE, MARIO · 2020 to 2024
$3.1M
NCI NIH HHS P30 CA008748NIAID NIH HHS U01 AI147462NIAMS NIH HHS U01 AR077511
6 · The paper itself

Abstract

Immune checkpoint inhibitors have emerged as a pillar in the management of advanced malignancies. However, nonspecific immune activation may lead to immune-related adverse events, wherein the skin and its appendages are the most frequent targets. Cutaneous immune-related adverse events include a diverse group of inflammatory reactions, with maculopapular rash, pruritus, psoriasiform and lichenoid eruptions being the most prevalent subtypes. Cutaneous immune-related adverse events occur early, with maculopapular rash presenting within the first 6 weeks after the initial immune checkpoint inhibitor dose. Management involves the use of topical corticosteroids for mild to moderate (grades 1-2) rash, addition of systemic corticosteroids for severe (grade 3) rash, and discontinuation of immunotherapy with grade 4 rash. Bullous pemphigoid eruptions, vitiligo-like skin hypopigmentation/depigmentation, and psoriasiform rash are more often attributed to programmed cell death-1/programmed cell death ligand-1 inhibitors. The treatment of bullous pemphigoid eruptions is similar to the treatment of maculopapular rash and lichenoid eruptions, with the addition of rituximab in grade 3-4 rash. Skin hypopigmentation/depigmentation does not require specific dermatologic treatment aside from photoprotective measures. In addition to topical corticosteroids, psoriasiform rash may be managed with vitamin D

Indexed as

Drug EruptionsHumansImmune Checkpoint InhibitorsNeoplasmsImmune Checkpoint Inhibitorscheckpoint inhibitorCTLA-4 inhibitordermatologic adverse eventimmune-related cutaneous adverse eventlichenoid eruptionmaculopapular rashPD-1 inhibitorPD-L1 inhibitorpruritusvitiligo

Identifiers

PMID32454097
PMCPMC7572894
OpenAlexW3027845041

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.